US · Healthcare · Medical Devices
EPS came in at 0.30 against a street estimate of 0.61 — a miss of 50.8%.
Analysts rate TransMedics Group Inc a buy (6 buy, 3 hold, 0 sell out of 9) with an average price target of $109.60.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.32% |
| FMR Inc | 14.75% |
| Vanguard Portfolio Management, LLC | 5.55% |
| Vanguard Capital Management, LLC | 4.28% |
| State Street Corp | 3.82% |
| Amvescap Plc. | 3.00% |
| UBS Asset Mgmt Americas Inc | 2.72% |
| Delaware Management Holdings Inc | 2.56% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-05-21 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-10 |
| Results announced · Q1 2026 | 2026-02-27 |
| Annual report FY2025 | 2026-02-24 |
| Results announced · Q1 2026 | 2026-02-24 |
| Quarterly report · Q3 2025 | 2025-10-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for TransMedics Group Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.